Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

71 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The effect of sauna bathing on lipid profile in young, physically active, male subjects.
Gryka D, Pilch W, Szarek M, Szygula Z, Tota Ł. Gryka D, et al. Among authors: szarek m. Int J Occup Med Environ Health. 2014 Aug;27(4):608-18. doi: 10.2478/s13382-014-0281-9. Epub 2014 Jul 7. Int J Occup Med Environ Health. 2014. PMID: 25001587
Fatty acids composition in erythrocyte membranes of athletes after one and after a series of whole body cryostimulation sessions.
Kepinska M, Gdula-Argasinska J, Dabrowski Z, Szarek M, Pilch W, Kreska-Korus A, Szygula Z. Kepinska M, et al. Among authors: szarek m. Cryobiology. 2017 Feb;74:121-125. doi: 10.1016/j.cryobiol.2016.11.005. Epub 2016 Nov 18. Cryobiology. 2017. PMID: 27871847
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Verma S, Lapuerta P, Pitt B; SOLOIST-WHF Trial Investigators. Bhatt DL, et al. Among authors: szarek m. N Engl J Med. 2020 Nov 16. doi: 10.1056/NEJMoa2030183. Online ahead of print. N Engl J Med. 2020. PMID: 33200892
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM, Bailey CJ, Díaz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PG; SCORED Investigators. Bhatt DL, et al. Among authors: szarek m. N Engl J Med. 2020 Nov 16. doi: 10.1056/NEJMoa2030186. Online ahead of print. N Engl J Med. 2020. PMID: 33200891
Response by Schwartz et al to Letter Regarding Article, "Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial".
Schwartz GG, Szarek M, Bittner VA, Steg PG. Schwartz GG, et al. Among authors: szarek m. Circulation. 2020 Nov 17;142(20):e335-e336. doi: 10.1161/CIRCULATIONAHA.120.050609. Epub 2020 Nov 16. Circulation. 2020. PMID: 33196306 No abstract available.
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial.
Szarek M, Bittner VA, Aylward P, Baccara-Dinet M, Bhatt DL, Diaz R, Fras Z, Goodman SG, Halvorsen S, Harrington RA, Jukema JW, Moriarty PM, Pordy R, Ray KK, Sinnaeve P, Tsimikas S, Vogel R, White HD, Zahger D, Zeiher AM, Steg PG, Schwartz GG; ODYSSEY OUTCOMES Investigators. Szarek M, et al. Eur Heart J. 2020 Oct 14:ehaa649. doi: 10.1093/eurheartj/ehaa649. Online ahead of print. Eur Heart J. 2020. PMID: 33051646
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial.
Tuñón J, Steg PG, Bhatt DL, Bittner VA, Díaz R, Goodman SG, Jukema JW, Kim YU, Li QH, Mueller C, Parkhomenko A, Pordy R, Sritara P, Szarek M, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators. Tuñón J, et al. Among authors: szarek m. Eur Heart J. 2020 Aug 21:ehaa498. doi: 10.1093/eurheartj/ehaa498. Online ahead of print. Eur Heart J. 2020. PMID: 32820320
Reply: Hemorrhagic Stroke, All-Cause Death, and Intensive LDL-C Lowering: Evidence From SPARCL and Beyond.
Szarek M, Amarenco P, Callahan A, Goldstein LB, Sillesen H, Welch KM; SPARCL Committees and Investigators. Szarek M, et al. J Am Coll Cardiol. 2020 Aug 18;76(7):886-888. doi: 10.1016/j.jacc.2020.06.042. J Am Coll Cardiol. 2020. PMID: 32792087 No abstract available.
Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial.
Diaz R, Li QH, Bhatt DL, Bittner VA, Baccara-Dinet MT, Goodman SG, Jukema JW, Kimura T, Parkhomenko A, Pordy R, Reiner Ž, Roe MT, Szarek M, Tse HF, White HD, Zahger D, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Diaz R, et al. Among authors: szarek m. Eur J Prev Cardiol. 2020 Jul 27:2047487320941987. doi: 10.1177/2047487320941987. Online ahead of print. Eur J Prev Cardiol. 2020. PMID: 32718237 Free article.
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial.
Bhatt DL, Briggs AH, Reed SD, Annemans L, Szarek M, Bittner VA, Diaz R, Goodman SG, Harrington RA, Higuchi K, Joulain F, Jukema JW, Li QH, Mahaffey KW, Sanchez RJ, Roe MT, Lopes RD, White HD, Zeiher AM, Schwartz GG, Gabriel Steg P; ODYSSEY OUTCOMES Investigators. Bhatt DL, et al. Among authors: szarek m. J Am Coll Cardiol. 2020 May 12;75(18):2297-2308. doi: 10.1016/j.jacc.2020.03.029. J Am Coll Cardiol. 2020. PMID: 32381160 Free article.
71 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback